Skip to main navigation
  Menu

ASLAN Pharmaceuticals

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
EN
english中文

Investor Relations

Investor Relations

  • Investor Home
  • Corporate Information
  • Stock Information
  • News & Events
  • Financial Information
  • Shareholder Services

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Alerts sign up

Required fields denoted by an asterisk ().
Alert type

About ASLAN

About ASLAN

ASLAN Pharmaceuticals is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.

News Releases
Date Title
May 20, 2022
ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting
May 18, 2022
ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 10, 2022
ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual Meeting
Read More

Investor Relations
E-mail: investor@aslanpharma.com

Shareholder Tools

  • Print Page

    Print Page

  • RSS Feeds

    RSS Feeds

  • E-mail Alerts

    E-mail Alerts

Company

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
  • Terms and Conditions

Careers

For more information on employment opportunities at ASLAN, please contact us at careers@aslanpharma.com

Contact Us

Singapore Headquarters
83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
Tel: +65 6222 4235
Fax: +65 6225 2419

contact@aslanpharma.com